Form 4 for STLN Starling Oncology, Inc.
Accepted 2026-06-09 19:06:28 ET · period of report 2026-06-08 · accession 0001079973-26-000801 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| T | 2026-06-09 19:06 | 2026-06-08 | STLN | Podnos Yale | Chief Medical Off | S - Sale | $5.38 | -23.5K | 259.5K | -8% | -$126.1K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-06-08 | S | D | 23,451 | $5.38 | 259,527 | D | — | — | (F1) Price is the volume weighted average selling price of all sales on behalf of the Reporting Person on June 8, 2028 within a one-dollar range. Actual prices ranged from $5.35 to $5.42. The Reporting Person hereby undertakes to provide upon request of the Commission staff full information regarding the number of shares sold at each separate price. (F2) Sales were made on behalf of the Reporting Person pursuant to the Rule 10b5-1(c) plan that was adopted on 08/26/2025. |